Financial Communications

2024

17/10/2024	IntegraGen - H1 2024 results - Sales up 6% on a like-for-like basis (excluding SeqOIA) and profitability maintained
18/07/2024	IntegraGen - Sales up 6% and cash position of €2.8m
18/04/2024	IntegraGen - 2023 annual results: 5% decline in revenues and positive EBITDA
13/01/2024	IntegraGen - 2023 sales and cash position

2023

19/10/2023	IntegraGen - H1 2023 results - Sales down 13% and resilient profitability
13/07/2023	IntegraGen - First-half 2023 sales of €5.6m, down 13% on H1 2022, and cash position of €4.3m
24/04/2023	IntegraGen - 2022 annual results: 16% revenue growth and positive EBITDA
13/01/2023	IntegraGen - 2022 sales and cash position

2022

18/10/2022	Half-year results 2022 - Strong growth in 35% revenues and improved profitability
13/07/2022	First-half 2022 sales of €6.4m, up +34% on H1 2021, and cash position of €4.5m
29/04/2022	IntegraGen - 2021 annual results: strong 201TP3Q growth in revenues from ongoing operations and marked improvement in profitability
14/01/2022	IntegraGen - 2021 sales and cash position

2021

08/10/2021	IntegraGen - Half-year results 2021
16/07/2021	First-half 2021 sales of €4.8m, up +2% on 2020, and cash position of €4.3m
16/04/2021	Integragen - 2020 annual results: growth in revenues from ongoing operations (+101TP3Q) and EBITDA close to breakeven for the year
12/01/2020	IntegraGen - 2020 sales and cash position

2020

16/11/2020	Successful friendly takeover bid by OncoDNA for IntegraGen shares
18/09/2020	IntegraGen - 1st half 2020 results
09/07/2020	Agreement on a friendly takeover bid by OncoDNA for IIntegraGen
03/04/2020	IntegraGen - Annual results 2019
26/03/2020	IntegraGen announces agreement with leading US cancer center to use MERCURY™
11/03/2020	IntegraGen renews partnership agreement with Institut Pasteur
10/01/2020	IntegraGen - 2019 sales and cash position